No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACAD240517P16000
- 1.00
- +0.05+5.26%
15min DelayClose May 9 16:00 ET
1.00High0.66Low
0.70Open0.95Pre Close29 Volume3.24K Open Interest16.00Strike Price2.67KTurnover77.04%IV-2.53%PremiumMay 17, 2024Expiry Date0.79Intrinsic Value100Multiplier8DDays to Expiry0.21Time Value100Contract SizeAmericanOptions Type-0.6437Delta0.2112Gamma12.94Leverage Ratio-0.0392Theta-0.0022Rho-8.33Eff Leverage0.0086Vega
Intraday
- 5D
- 1D
News
ACADIA Pharmaceuticals | 10-Q: Quarterly report
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.
ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30.19 to $30.